scispace - formally typeset
A

Alan Sher

Researcher at National Institutes of Health

Publications -  508
Citations -  72497

Alan Sher is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Schistosoma mansoni & Immune system. The author has an hindex of 132, co-authored 486 publications receiving 68128 citations. Previous affiliations of Alan Sher include National Institute for Medical Research & University of Louisville.

Papers
More filters
Journal ArticleDOI

Functional diversity of helper T lymphocytes.

TL;DR: The existence of subsets of CD4+ helper T lymphocytes that differ in their cytokine secretion patterns and effector functions provides a framework for understanding the heterogeneity of normal and pathological immune responses.
Journal ArticleDOI

Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion and green fluorescent protein reporter gene insertion.

TL;DR: Defying anticipated FKN functions, absence of CX3CR1 interferes neither with monocyte extravasation in a peritonitis model nor with DC migration and differentiation in response to microbial antigens or contact sensitizers.
Journal ArticleDOI

Type I interferons in infectious disease.

TL;DR: Experimental models of tuberculosis have demonstrated that prostaglandin E2 and interleukin-1 inhibit type I IFN expression and its downstream effects, demonstrating that a cross-regulatory network of cytokines operates during infectious diseases to provide protection with minimum damage to the host.
Journal ArticleDOI

Vaccine Adjuvants: Putting Innate Immunity to Work

TL;DR: There remains a need for improved adjuvants that enhance protective antibody responses, especially in populations that respond poorly to current vaccines, and the larger challenge is to develop vaccines that generate strong T cell immunity with purified or recombinant vaccine antigens.
Journal ArticleDOI

Cooperation of Toll-like receptor signals in innate immune defence.

TL;DR: This Review highlights recent advances in the newly emerging field of TLR cooperation and discusses their implications for the development of adjuvants and immunotherapies.